Living systematic review of 11 RCTs (7359 participants) with meta-analysis in COPD: biologic therapies reduced annual exacerbation rate (MD -0.16; high certainty) but probably not 52-week exacerbation risk (RR 1.00); FEV1 and quality-of-life effects not clinically important.
Meta-analysisn = 7,359
García Morales et al. Biological therapy for chronic obstructive pulmonary disease (COPD): Effectiveness and safety